FDA Oncologic Drugs Advisory Committee Votes in Favor of Daiichi Sankyo ’s Pexidartinib for the Treatment of Select Patients with TGCT, a Rare, Debilitating Tumor

Tokyo and Basking Ridge, NJ– (May 14, 2019)– Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted (Vote: 12 yes, 3...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials